Gathering and analyzing patient experience data in a real-world setting is a key challenge for many

By HEOR Staff Writer

January 18, 2023

Gathering and analyzing patient experience data in a real-world setting is a key challenge for many. To explore this further, ISPOR in Vienna held a second plenary panel featuring experts in the field. What did they discuss?

The panel discussed the importance of rigor in choosing, implementing, and analyzing patient experience data in non-randomized, uncontrolled study designs. Dr. Burgos spoke about the Darwin EU initiative and the importance of stakeholder engagement and capacity building to facilitate patient experience data collection. Professor Devlin discussed the implementation of patient-reported outcome data capture and the PROMs initiatives in the UK, Canada, and New Zealand. Dr. Perfetto spoke about the Core Impact initiative in the US, which standardizes patient experience data collection and the use of core outcome sets.

The panel highlighted the need for further guidance and collaboration with stakeholders to ensure patient experience data is used to inform regulatory decision-making.

Reference url

Recent Posts

Lingjian Morphology Diagnostics
Lingjian Morphology Diagnostics Transforming Clinical Laboratory Practices

By HEOR Staff Writer

June 22, 2026

Lingjian Morphology Diagnostics transforms microscopic analysis in clinical laboratories by uniting image interpretation, cell classification, morphological description, target localization, and natural language interaction within a single vision-language architecture. Developed to overcome pract...
vulnerable elderly care
Mapping Vulnerable Elderly Care in the Netherlands

By HEOR Staff Writer

June 22, 2026

As the Netherlands confronts rapid societal aging, effective vulnerable elderly care has become an urgent policy priority. One in four community-dwelling adults aged 65 and older lives with vulnerable health, according to Longitudinal Aging Study Amsterdam (LASA) data, marking a critical target g...
Joint Scientific Consultation EU
Joint Scientific Consultation EU Strategies for Medical Device Companies

By João L. Carapinha

June 19, 2026

The EU Joint Scientific Consultation gives medical device developers a voluntary route to obtain targeted feedback on clinical evidence plans well before formal Joint Clinical Assessment and national reimbursement decisions. Manufacturers of select high-risk technologies can align their developme...